Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC811007 in adults with type 2 diabetic nephropathy
ACTRN12612000959875Phase 2Completed
- Sponsor
- Protemix
- Start
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing GC811007 with Placebo (2 arms). Primary endpoint: Rate of decline in renal function. Started Nov 2001; status: completed.
02
Drugs
trientine
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ACTRN12612000959875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000959875.